Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accumulated Expenses (2016 - 2019)

Historic Accumulated Expenses for Neurocrine Biosciences (NBIX) over the last 10 years, with Q4 2019 value amounting to $38.9 million.

  • Neurocrine Biosciences' Accumulated Expenses rose 4242.71% to $38.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $38.9 million, marking a year-over-year increase of 4242.71%. This contributed to the annual value of $38.9 million for FY2019, which is 4242.71% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Accumulated Expenses stood at $38.9 million for Q4 2019, which was up 4242.71% from $27.3 million recorded in Q4 2018.
  • Neurocrine Biosciences' 5-year Accumulated Expenses high stood at $38.9 million for Q4 2019, and its period low was $9.6 million during Q4 2016.
  • Its 5-year average for Accumulated Expenses is $19.5 million, with a median of $18.7 million in 2015.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 4977.93% in 2016, then soared by 16049.8% in 2017.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Accumulated Expenses stood at $19.0 million in 2015, then crashed by 49.78% to $9.6 million in 2016, then surged by 160.5% to $24.9 million in 2017, then rose by 9.8% to $27.3 million in 2018, then skyrocketed by 42.43% to $38.9 million in 2019.
  • Its last three reported values are $38.9 million in Q4 2019, $27.3 million for Q4 2018, and $24.9 million during Q4 2017.